Report : North America Cell Line Development Serum Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Type (Fetal Bovine Serum, Adult Bovine Serum, Porcine Serum, Horse Serum, Other Animal Serum); By Application (Bioproduction, Drug Discovery, Tissue Engineering and Regenerative Medicines, Toxicity Testing, Academic Research); and Country
According to a new market research study of “North America Cell Line Development Serum Market Forecast to 2027 - COVID-19 Impact and Analysis by Type and Application.” The North America cell line development serum market is expected to reach US$ 502.91 Mn in 2027 from US$ 307.29 Mn in 2019. The market is estimated to grow with a CAGR of 6.4% from 2020-2027. The report highlights trends prevailing in the North America cell line development serum market and the factors driving market along with those that act as hindrances.
The North America cell line development serum market, based on type, has been segmented into fetal bovine serum, adult bovine serum, porcine serum, horse serum, other animal serum. Fetal bovine serum segment held the largest share and is expected to register the highest CAGR in the market during the forecast period.
The cell line can be defined as cell culture, selected for uniformity from a cell population derived from a usually homogeneous tissue source in a growing medium under controlled conditions. The serum serves as a carrier for enzymes, micronutrients, lipids, and trace elements into the cell and regulates cell membrane permeability. Tissue Engineering has now evolved into the broader area of regenerative medicine, which focuses on developing clinical therapies for the maintenance, repair, replacement, and enhancement of biological function, using cell engineering. Regenerative therapies using cell lines and culture can help the researchers in early-intervention treatment for degenerative diseases and traumatic injuries. Thus, a surge in the use of regenerative medicines propels the cell line development serum market.
Key factors that are driving growth of the North America cell line development serum market are increasing adoption of regenerative medicines, rising prevalence of cancer across the globe and increasing investments in R&D by pharmaceutical and biotechnology companies. However, risks associated with cell line contamination is expected to hamper the market during the forecast period.
Lonza, Thermo Fisher Scientific Inc. and Sigma-Aldrich Corporation (Merck KGaA) are among the leading companies operating in the North America cell line development serum market.
- Fetal Bovine Serum
- Adult Bovine Serum
- Porcine Serum
- Horse Serum
- Other Animal Serum
- Drug Discovery
- Tissue Engineering and Regenerative Medicines
- Toxicity Testing
- Academic Research
Contact Person: Sameer Joshi
Email Id: email@example.com